Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from SinoMab Bioscience Ltd. ( (HK:3681) ).
SinoMab BioScience Limited has successfully completed the subscription of new shares under a general mandate, issuing a total of 112,810,817 shares. This issuance represents approximately 9.37% of the company’s enlarged share capital and has raised net proceeds of about HK$123,956,911, which will be used as previously disclosed. This move is expected to impact the company’s shareholding structure and potentially enhance its financial position and market presence.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biotechnology company based in Hong Kong, focusing on the development and commercialization of therapeutics for the treatment of immunological diseases. The company is involved in the research and development of monoclonal antibody-based biologics.
Average Trading Volume: 553,893
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.32B
For an in-depth examination of 3681 stock, go to TipRanks’ Stock Analysis page.